Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 565

1.

Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?

Serretta V, Valerio MR, Costa R, Tripoli V, Morabito A, Princiotta A, Scalici Gesolfo C, Borsellino N, Verderame F, Gebbia V, Licari M, Sanfilippo C; members of the GSTU Foundation.

Urol Oncol. 2019 Oct 7. pii: S1078-1439(19)30327-8. doi: 10.1016/j.urolonc.2019.08.009. [Epub ahead of print]

PMID:
31601517
2.

Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib.

Esposito Abate R, Pasquale R, Sacco A, Piccirillo MC, Morabito A, Bidoli P, Finocchiaro G, Chiari R, Foltran L, Buosi R, Tiseo M, Giannetta L, Battiloro C, Fasola G, Romano G, Ciuffreda L, Frassoldati A, de Marinis F, Cappuzzo F, Normanno N.

Cancers (Basel). 2019 Sep 25;11(10). pii: E1431. doi: 10.3390/cancers11101431.

3.

Pembrolizumab in lung cancer: current evidence and future perspectives.

Palumbo G, Carillio G, Manzo A, Montanino A, Sforza V, Costanzo R, Sandomenico C, Manna C, Luca G, Piccirillo MC, Daniele G, Cecio R, Botti G, Totaro G, Muto P, Picone C, Esposito G, Normanno N, Morabito A.

Future Oncol. 2019 Aug 21. doi: 10.2217/fon-2019-0073. [Epub ahead of print]

PMID:
31432705
4.

Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial.

Landi L, Chiari R, Tiseo M, D'Incà F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis DL, De Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, Grossi F, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Alì G, Bruno R, Proietti A, Fontanini G, Crinò L, Cappuzzo F.

Clin Cancer Res. 2019 Aug 15. pii: clincanres.0994.2019. doi: 10.1158/1078-0432.CCR-19-0994. [Epub ahead of print]

PMID:
31416808
5.

3D Virtual Reconstruction of the Ancient Roman Incile of the Fucino Lake.

Di Angelo L, Di Stefano P, Guardiani E, Morabito AE, Pane C.

Sensors (Basel). 2019 Aug 10;19(16). pii: E3505. doi: 10.3390/s19163505.

6.

Industrial air pollution and mortality in the Taranto area, Southern Italy: A difference-in-differences approach.

Leogrande S, Alessandrini ER, Stafoggia M, Morabito A, Nocioni A, Ancona C, Bisceglia L, Mataloni F, Giua R, Mincuzzi A, Minerba S, Spagnolo S, Pastore T, Tanzarella A, Assennato G, Forastiere F; CSA Puglia Study Group (see acknowledgements).

Environ Int. 2019 Nov;132:105030. doi: 10.1016/j.envint.2019.105030. Epub 2019 Aug 6.

7.

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study.

Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Märten A, Cufer T.

Future Oncol. 2019 Sep;15(25):2905-2914. doi: 10.2217/fon-2019-0346. Epub 2019 Aug 2.

8.

Modeling, Assessment, and Design of Porous Cells Based on Schwartz Primitive Surface for Bone Scaffolds.

Ambu R, Morabito AE.

ScientificWorldJournal. 2019 Jun 27;2019:7060847. doi: 10.1155/2019/7060847. eCollection 2019.

9.

Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-ß1 and miRNA21 cooperation.

Camerlingo R, Miceli R, Marra L, Rea G, D'Agnano I, Nardella M, Montella R, Morabito A, Normanno N, Tirino V, Rocco G.

PLoS One. 2019 Jul 25;14(7):e0219597. doi: 10.1371/journal.pone.0219597. eCollection 2019.

10.

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.

Capelletto E, Migliorino MR, Morabito A, Chiari R, Grossi F, Tiseo M, Costanzo FD, Delmonte A, Romano G, Galetta D, Scotti V, Gregorc V, Pisconti S, Ceresoli GL, Del Conte A, Ciuffreda L, Colantonio I, Bria E, Ricciardi S, Manzo A, Metro G, Morelli AM, Critelli R, Pacchiana MV, Stura I, Migliaretti G, Novello S.

Lung Cancer. 2019 Aug;134:210-217. doi: 10.1016/j.lungcan.2019.06.028. Epub 2019 Jun 27.

PMID:
31319983
11.

Restoring gut physiology in short bowel patients: from bench to clinical application of autologous intestinal reconstructive procedures.

Lauro A, Coletta R, Morabito A.

Expert Rev Gastroenterol Hepatol. 2019 Aug;13(8):785-796. doi: 10.1080/17474124.2019.1640600. Epub 2019 Jul 15.

PMID:
31282770
12.

Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials.

Martino M, Rossi M, Ferreri A, Loteta B, Morabito A, Moscato T, Console G, Innao V, Naso V, Provenzano PF, Recchia AG, Gentile M.

Expert Rev Hematol. 2019 Aug;12(8):665-684. doi: 10.1080/17474086.2019.1634541. Epub 2019 Jul 3.

PMID:
31251688
13.

IFN-γ upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1/PD-L1 blockade.

Pistillo MP, Carosio R, Banelli B, Morabito A, Mastracci L, Ferro P, Varesano S, Venè R, Poggi A, Roncella S.

Cell Mol Immunol. 2019 Jun 19. doi: 10.1038/s41423-019-0245-x. [Epub ahead of print] No abstract available.

PMID:
31217525
14.

Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials.

Morabito A, Piccirillo MC, Maione P, Luciani A, Cavanna L, Bonanno L, Filipazzi V, Leo S, Cinieri S, Morgillo F, Burgio MA, Ferrara D, Rosetti F, Bianco R, Artioli F, Cortinovis D, Gebbia V, Fregoni V, Mencoboni M, Sandomenico C, Rossi A, Montanino A, Manzo A, Rocco G, Arenare L, Daniele G, Signoriello S, Gallo C, Perrone F, Gridelli C.

Lung Cancer. 2019 Jul;133:62-68. doi: 10.1016/j.lungcan.2019.05.009. Epub 2019 May 9.

PMID:
31200830
15.

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.

West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F.

Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.

PMID:
31122901
16.

Variations in the Detection of Anorectal Anomalies at Birth among European Cities.

Aldeiri B, Davidson JR, Eaton S, Coletta R, Cardoso Almeida A, Long AM, Knight M, Cross KM, Chouikh T, Iacobelli BD, Sarnacki S, Bagolan P, Cretolle C, Siminas S, Curry JI, Morabito A, De Coppi P.

Eur J Pediatr Surg. 2019 Apr 30. doi: 10.1055/s-0039-1687868. [Epub ahead of print]

PMID:
31039595
17.

Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34+ Cell and Platelet Counts.

Martino M, Gori M, Moscato T, Naso V, Ferreri A, Provenzano F, Loteta B, Sanguedolce MC, Console G, Dattola A, Pucci G, Gentile M, Morabito A, Recchia AG, Tripepi G, Pitino A.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1586-1591. doi: 10.1016/j.bbmt.2019.04.011. Epub 2019 Apr 17.

PMID:
31002994
18.

Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.

Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A, Vitiello F, Lo Russo G, Parra HS, Cortesi E, Cappuzzo F, Calabrò L, Tiseo M, Turci D, Gamucci T, Antonelli P, Morabito A, Chella A, Giannarelli D, Galetta D.

Oncologist. 2019 Apr 17. pii: theoncologist.2018-0737. doi: 10.1634/theoncologist.2018-0737. [Epub ahead of print]

PMID:
30996007
19.

Toward a better definition of EPCAM deletions in Lynch Syndrome: Report of new variants in Italy and the associated molecular phenotype.

Cini G, Quaia M, Canzonieri V, Fornasarig M, Maestro R, Morabito A, D'Elia AV, Urso ED, Mammi I, Viel A.

Mol Genet Genomic Med. 2019 May;7(5):e587. doi: 10.1002/mgg3.587. Epub 2019 Mar 27.

20.

Total esophagogastric dissociation (TEGD): Lessons from two decades of experience.

Coletta R, Aldeiri B, Jackson R, Morabito A.

J Pediatr Surg. 2019 Jun;54(6):1214-1219. doi: 10.1016/j.jpedsurg.2019.02.031. Epub 2019 Feb 28.

PMID:
30898397
21.

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients.

Rachiglio AM, Fenizia F, Piccirillo MC, Galetta D, Crinò L, Vincenzi B, Barletta E, Pinto C, Ferraù F, Lambiase M, Montanino A, Roma C, Ludovini V, Montagna ES, De Luca A, Rocco G, Botti G, Perrone F, Morabito A, Normanno N.

Cancers (Basel). 2019 Mar 10;11(3). pii: E341. doi: 10.3390/cancers11030341.

22.

Improving our knowledge in PD-L1 testing in lung cancer: the archival sample is 'promoted'!

Morabito A.

Ann Oncol. 2019 Feb 1;30(2):165-167. doi: 10.1093/annonc/mdy556. No abstract available.

PMID:
30715154
23.

Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology.

Pascarella G, Capasso A, Nardone A, Triassi M, Pignata S, Arenare L, Ascierto P, Curvietto M, Maiolino P, D'Aniello R, Montanino A, Laudato F, De Feo G, Botti G, Perrone F, Petrillo A, Cavalcanti E, Lastoria S, Maurea N, Morabito A.

PLoS One. 2019 Jan 8;14(1):e0210330. doi: 10.1371/journal.pone.0210330. eCollection 2019.

24.

Multiple effectiveness aspects of tapentadol for moderate-severe cancer-pain treatment: an observational prospective study.

Cascella M, Forte CA, Bimonte S, Esposito G, Romano C, Costanzo R, Morabito A, Cuomo A.

J Pain Res. 2018 Dec 24;12:117-125. doi: 10.2147/JPR.S181079. eCollection 2019.

25.

Non-transplant Surgical Management of Short Bowel Syndrome in Children: An Overview.

Coletta R, Morabito A.

Curr Pediatr Rev. 2019;15(2):106-110. doi: 10.2174/1573396315666181129164112.

PMID:
30499416
26.

Long-term mortality in obese subjects undergoing malabsorptive surgery (biliopancreatic diversion and biliointestinal bypass) versus medical treatment.

Ceriani V, Sarro G, Micheletto G, Giovanelli A, Zakaria AS, Fanchini M, Osio C, Nosari I, Morabito A, Pontiroli AE; LAGB10 working group.

Int J Obes (Lond). 2019 Jun;43(6):1147-1153. doi: 10.1038/s41366-018-0244-5. Epub 2018 Nov 23.

PMID:
30470806
27.

The role of circulating free DNA in the management of NSCLC.

Esposito Abate R, Pasquale R, Fenizia F, Rachiglio AM, Roma C, Bergantino F, Forgione L, Lambiase M, Sacco A, Piccirillo MC, Morabito A, Normanno N.

Expert Rev Anticancer Ther. 2019 Jan;19(1):19-28. doi: 10.1080/14737140.2019.1548938. Epub 2018 Nov 29. Review.

PMID:
30462523
28.

Immune Checkpoints and Innovative Therapies in Glioblastoma.

Romani M, Pistillo MP, Carosio R, Morabito A, Banelli B.

Front Oncol. 2018 Oct 23;8:464. doi: 10.3389/fonc.2018.00464. eCollection 2018. Review.

29.

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.

Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Golembesky A, Märten A, Cufer T.

Future Oncol. 2018 Nov;14(27):2861-2874. doi: 10.2217/fon-2018-0711. Epub 2018 Oct 19.

30.

Expanding intestinal segment using osmotic hydrogel: An in vivo study.

Coletta R, Olivieri C, Persano G, Solari V, Inserra A, Morabito A.

J Biomed Mater Res B Appl Biomater. 2019 May;107(4):1304-1309. doi: 10.1002/jbm.b.34224. Epub 2018 Oct 12.

PMID:
30312527
31.

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.

Pistillo MP, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R, Banelli B, Ferrero F, Spano L, Tanda E, Ferrucci PF, Martinoli C, Cocorocchio E, Guida M, Tommasi S, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Quaglino P, Fava P, Osella-Abate S, Ascierto PA, Capone M, Simeone E, Romani M, Spagnolo F, Queirolo P; Italian Melanoma Intergroup (IMI).

Cancer Immunol Immunother. 2019 Jan;68(1):97-107. doi: 10.1007/s00262-018-2258-1. Epub 2018 Oct 11.

PMID:
30311027
32.

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S.

N Engl J Med. 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25.

33.

Messy Play Therapy in the Treatment of Food Aversion in a Patient With Intestinal Failure: Our Experience.

Chiatto F, Coletta R, Aversano A, Warburton T, Forsythe L, Morabito A.

JPEN J Parenter Enteral Nutr. 2019 Mar;43(3):412-418. doi: 10.1002/jpen.1433. Epub 2018 Sep 25.

PMID:
30251268
34.

Performance of tumor testing for Lynch syndrome identification in patients with colorectal cancer: A retrospective single-center study.

Signoroni S, Tibiletti MG, Ricci MT, Milione M, Perrone F, Pensotti V, Chiaravalli AM, Carnevali I, Morabito A, Bertario L, Vitellaro M.

Tumori. 2019 Feb;105(1):76-83. doi: 10.1177/0300891618792460. Epub 2018 Aug 17.

PMID:
30117378
35.

Laparoscopic Curative Resection for Rectal Cancer: A Cohort Study on Long-term Outcome.

Portale G, Valdegamberi A, Cavallin F, Morabito A, Frigo F, Fiscon V.

Surg Laparosc Endosc Percutan Tech. 2018 Oct;28(5):318-323. doi: 10.1097/SLE.0000000000000565.

PMID:
30074527
36.

Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials.

Gridelli C, Morabito A, Cavanna L, Luciani A, Maione P, Bonanno L, Filipazzi V, Leo S, Cinieri S, Ciardiello F, Burgio MA, Bilancia D, Cortinovis D, Rosetti F, Bianco R, Gebbia V, Artioli F, Bordonaro R, Fregoni V, Mencoboni M, Nelli F, Riccardi F, di Isernia G, Costanzo R, Rocco G, Daniele G, Signoriello S, Piccirillo MC, Gallo C, Perrone F.

J Clin Oncol. 2018 Sep 1;36(25):2585-2592. doi: 10.1200/JCO.2017.76.8390. Epub 2018 Jul 20.

PMID:
30028656
37.

Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy.

Gridelli C, Ascierto PA, Grossi F, Baldini E, Favaretto A, Garassino MC, Morabito A, Migliorino MR, Rossi A, de Marinis F.

Curr Clin Pharmacol. 2018;13(2):76-84. doi: 10.2174/1574884713666180711160008.

PMID:
29992894
38.

Institutional Experience with Spiral Intestinal Lengthening and Tailoring.

Coletta R, Aldeiri B, Morabito A.

Eur J Pediatr Surg. 2018 Jun 19. doi: 10.1055/s-0038-1660850. [Epub ahead of print]

PMID:
29920633
39.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.

Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC.

JAMA Oncol. 2018 Sep 1;4(9):1189-1197. doi: 10.1001/jamaoncol.2018.0775.

40.

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab.

Queirolo P, Dozin B, Morabito A, Banelli B, Carosio R, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Ascierto PA, Madonna G, Simeone E, De Galitiis F, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Ghilardi L, Merelli B, Fava P, Osella-Abate S, Guidoboni M, Romani M, Ferone D, Spagnolo F, Pistillo MP; Italian Melanoma Intergroup (IMI).

Eur J Cancer. 2018 Jul;97:59-61. doi: 10.1016/j.ejca.2018.04.005. Epub 2018 May 7. No abstract available.

PMID:
29743138
41.

Outcomes in patients with short bowel syndrome after autologous intestinal reconstruction: Does etiology matter?

Pederiva F, Sgrò A, Coletta R, Khalil B, Morabito A.

J Pediatr Surg. 2018 Jul;53(7):1345-1350. doi: 10.1016/j.jpedsurg.2018.03.009. Epub 2018 Mar 12.

PMID:
29628209
42.

Impact of Short Bowel Syndrome on Quality of Life and Family: The Patient's Perspective.

Pederiva F, Khalil B, Morabito A, Wood SJ.

Eur J Pediatr Surg. 2019 Apr;29(2):196-202. doi: 10.1055/s-0037-1621737. Epub 2018 Jan 30.

PMID:
29532454
43.

Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.

Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP.

Front Immunol. 2018 Mar 2;9:403. doi: 10.3389/fimmu.2018.00403. eCollection 2018.

44.

Abrogation of TGF-beta signalling in TAGLN expressing cells recapitulates Pentalogy of Cantrell in the mouse.

Aldeiri B, Roostalu U, Albertini A, Behnsen J, Wong J, Morabito A, Cossu G.

Sci Rep. 2018 Feb 26;8(1):3658. doi: 10.1038/s41598-018-21948-z.

45.
46.

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.

Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Jänne PA, Yang JC.

Ann Oncol. 2018 Mar 1;29(3):687-693. doi: 10.1093/annonc/mdx820.

PMID:
29293889
47.

MicroRNA in Glioblastoma: An Overview.

Banelli B, Forlani A, Allemanni G, Morabito A, Pistillo MP, Romani M.

Int J Genomics. 2017;2017:7639084. doi: 10.1155/2017/7639084. Epub 2017 Nov 6. Review.

48.

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.

Metro G, Passaro A, Lo Russo G, Bonanno L, Giusti R, Gregorc V, Capelletto E, Martelli O, Cecere FL, Giannarelli D, Luciani A, Bearz A, Tuzi A, Scotti V, Tonini G, Galetta D, Carta A, Soto Parra H, Rebonato A, Morabito A, Chiari R.

Future Oncol. 2018 Feb;14(4):353-361. doi: 10.2217/fon-2017-0441. Epub 2017 Nov 14.

PMID:
29135281
49.

Clinical states of cirrhosis and competing risks.

D'Amico G, Morabito A, D'Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG.

J Hepatol. 2018 Mar;68(3):563-576. doi: 10.1016/j.jhep.2017.10.020. Epub 2017 Oct 27. Review.

PMID:
29111320
50.

Spatial distribution of kidney disease in the contaminated site of Taranto (Italy).

Benedetti M, De Santis M, Manno V, Minerba S, Mincuzzi A, Morabito A, Panocchia N, Soggiu ME, Tanzarella A, Pastore T, Bossola M, Giua R, Leogrande S, Nocioni A, Conti S, Comba P.

Am J Ind Med. 2017 Dec;60(12):1088-1099. doi: 10.1002/ajim.22781. Epub 2017 Oct 13.

PMID:
29027241

Supplemental Content

Loading ...
Support Center